Please use this identifier to cite or link to this item:
|Title:||Development of an in vitro assay and demonstration of Plasmodium berghei liver- Stage inhibition by TRAP-specific CD8+ T Cells|
|Authors:||Rhea J. Longley|
Katie J. Ewer
Adrian V.S. Hill
Alexandra J. Spencer
University of Oxford
Walter and Eliza Hall Institute of Medical Research
University of Melbourne
|Keywords:||Agricultural and Biological Sciences;Biochemistry, Genetics and Molecular Biology|
|Citation:||PLoS ONE. Vol.10, No.3 (2015)|
|Abstract:||© 2015 Longley et al. The development of an efficacious vaccine against the Plasmodium parasite remains a top priority. Previous research has demonstrated the ability of a prime-boost virally vectored sub-unit vaccination regimen, delivering the liver-stage expressed malaria antigen TRAP, to produce high levels of antigen-specific T cells. The liver-stage of malaria is the main target of T cell-mediated immunity, yet a major challenge in assessing new T cell inducing vaccines has been the lack of a suitable pre-clinical assay. We have developed a flow-cytometry based in vitro T cell killing assay using a mouse hepatoma cell line, Hepa1-6, and Plasmodium berghei GFP expressing sporozoites. Using this assay, P. berghei TRAP-specific CD8+T cell enriched splenocytes were shown to inhibit liver-stage parasites in an ef-fector- to-target ratio dependent manner. Further development of this assay using human hepatocytes and P. falciparum would provide a new method to pre-clinically screen vaccine candidates and to elucidate mechanisms of protection in vitro.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.